Blog

Will EpiVax Tools be the Ancer to Cancer?

EpiVax Oncology - New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about "EpiVax Oncology" in...

read more

$1.87M BioDefense Grant to EpiVax and CUBRC

CUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical...

read more

Creating Locally, Thinking Globally

EpiVax is now a member of Eurobiomed , a community bringing together scientific thought leaders with a common mission: Improve the health of all and as  quickly as possible. EpiVax, as a key player in the development of immunotherapies, will be in attendance at the...

read more